PSMA-617 的全化学合成:用于前列腺癌内治疗的原料药

IF 1.4 3区 化学 Q4 CHEMISTRY, INORGANIC & NUCLEAR
Kalangattu Sundaran Ajish Kumar, Anupam Mathur
{"title":"PSMA-617 的全化学合成:用于前列腺癌内治疗的原料药","authors":"Kalangattu Sundaran Ajish Kumar, Anupam Mathur","doi":"10.1515/ract-2023-0205","DOIUrl":null,"url":null,"abstract":"Synthesis of PSMA-617, a peptide based ligand used in the preparation of nuclear medicine, <jats:sup>177</jats:sup>Lu-PSMA-617, for the treatment of prostate cancer, is demonstrated in 6 steps, starting from appropriately protected amino acid building blocks. A solution phase Boc-strategy was adopted for the synthesis of peptide, wherein deprotection of carbamate group using HCl (g), was employed as the key step. The synthesis furnished PSMA-617 in purity &gt;99.5 % as confirmed by HPLC analysis. ESI-MS and NMR analysis supported the structural integrity of the compound. The synthesized ligand was radiolabelled using <jats:sup>177</jats:sup>Lu to generate the desired radiopharmaceutical, <jats:sup>177</jats:sup>Lu-PSMA-617, in radiochemical purity &gt;98 %, as revealed by radio HPLC and TLC analysis. This establishes its potential as a nuclear medicine for therapeutic application.","PeriodicalId":21167,"journal":{"name":"Radiochimica Acta","volume":"174 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Total chemical synthesis of PSMA-617: an API for prostate cancer endotherapeutic applications\",\"authors\":\"Kalangattu Sundaran Ajish Kumar, Anupam Mathur\",\"doi\":\"10.1515/ract-2023-0205\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Synthesis of PSMA-617, a peptide based ligand used in the preparation of nuclear medicine, <jats:sup>177</jats:sup>Lu-PSMA-617, for the treatment of prostate cancer, is demonstrated in 6 steps, starting from appropriately protected amino acid building blocks. A solution phase Boc-strategy was adopted for the synthesis of peptide, wherein deprotection of carbamate group using HCl (g), was employed as the key step. The synthesis furnished PSMA-617 in purity &gt;99.5 % as confirmed by HPLC analysis. ESI-MS and NMR analysis supported the structural integrity of the compound. The synthesized ligand was radiolabelled using <jats:sup>177</jats:sup>Lu to generate the desired radiopharmaceutical, <jats:sup>177</jats:sup>Lu-PSMA-617, in radiochemical purity &gt;98 %, as revealed by radio HPLC and TLC analysis. This establishes its potential as a nuclear medicine for therapeutic application.\",\"PeriodicalId\":21167,\"journal\":{\"name\":\"Radiochimica Acta\",\"volume\":\"174 1\",\"pages\":\"\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiochimica Acta\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1515/ract-2023-0205\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiochimica Acta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1515/ract-2023-0205","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0

摘要

从适当保护的氨基酸结构单元开始,通过 6 个步骤合成了 PSMA-617(一种用于制备治疗前列腺癌的核医学 177Lu-PSMA-617 的多肽配体)。肽的合成采用了溶液相 Boc 策略,其中关键步骤是使用 HCl (g) 对氨基甲酸酯基团进行脱保护。经 HPLC 分析证实,合成的 PSMA-617 纯度为 99.5%。ESI-MS 和 NMR 分析证实了该化合物结构的完整性。使用 177Lu 对合成的配体进行放射性标记,生成了所需的放射性药物 177Lu-PSMA-617,放射性 HPLC 和 TLC 分析表明其放射化学纯度为 98%。这证明了它作为治疗用核药的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Total chemical synthesis of PSMA-617: an API for prostate cancer endotherapeutic applications
Synthesis of PSMA-617, a peptide based ligand used in the preparation of nuclear medicine, 177Lu-PSMA-617, for the treatment of prostate cancer, is demonstrated in 6 steps, starting from appropriately protected amino acid building blocks. A solution phase Boc-strategy was adopted for the synthesis of peptide, wherein deprotection of carbamate group using HCl (g), was employed as the key step. The synthesis furnished PSMA-617 in purity >99.5 % as confirmed by HPLC analysis. ESI-MS and NMR analysis supported the structural integrity of the compound. The synthesized ligand was radiolabelled using 177Lu to generate the desired radiopharmaceutical, 177Lu-PSMA-617, in radiochemical purity >98 %, as revealed by radio HPLC and TLC analysis. This establishes its potential as a nuclear medicine for therapeutic application.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Radiochimica Acta
Radiochimica Acta 化学-核科学技术
CiteScore
2.90
自引率
16.70%
发文量
78
审稿时长
6 months
期刊介绍: Radiochimica Acta publishes manuscripts encompassing chemical aspects of nuclear science and technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信